MeVis Medical Solutions AG

Regulatory Filings • Oct 20, 2008

News Details

Corporate | 20 October 2008 11:30

MeVis taking the first key steps towards improving the early diagnosis of lung cancer with Visia™ CT Lung System:

MeVis Medical Solutions AG / Product Launch

Release of a Corporate News, transmitted by DGAP - a company of EquityStory
AG.
The issuer / publisher is solely responsible for the content of this announcement.

---

MeVis Medical Solutions launching a new software solution for the automatic
detection of lung nodules in multi-slice CT scans
• MeVis Visia™ Computer-Aided Detection (CAD) assists medical practitioners
in the early diagnosis of lung cancer
• Genuine medical added value thanks to improved diagnostics and optimized
work flows
• New marketing partnership with Invivo Corp., a subsidiary company of
Philips Healthcare

MeVis Medical Solutions AG (ISIN: DE000A0LBFE4), a specialist in software
for image-based medicine, has today announced the market launch by its US
subsidiary MeVis Medical Solutions, Inc. of a new software solution for
lung diagnostics in multi-slice computed tomography scans. With Visia™,
MeVis is broadening its range of specialized software solutions for the
improved early detection and diagnosis of common cancer illnesses.

'With Visia™, MeVis is now also offering medical practitioners highly
specialized software to assist in the early diagnosis of lung cancer, one
of the world’s most frequent types of cancer, which often leads to death,'
says Dr. Carl J.G. Evertsz, CEO of MeVis Medical Solutions AG. 'In this
way, we are able to further reinforce our position as an independent
producer of high-quality disease-oriented software solutions for combating
cancer.'

The software, which has already been cleared by the Food and Drug
Administration (FDA) in the United States and the Medical Devices Bureau of
Health Canada, automatically detects so-called solitary pulmonary nodules,
which may be an early indication of lung cancer. Visia™ also helps the
radiologist by providing an additional function known as AutoPoint™, which
allows the course of the illness and the effect of the therapy to be
reliably monitored. In addition, the software can automatically detect
embolism caused by an object blocking the arteries of the lung thanks to an
optional feature called Pulmonary Artery Patency Exam (PE™).

'We are pleased to report that Visia™ has met with an extremely favorable
response on the part of our OEM partners as well as clinical end-users
during the preliminary phase of the market launch,' says Thomas E. Tynes,
President & CEO of MeVis Medical Solu-tions, Inc. and CMO of MeVis Medical
Solutions AG. 'Radiologists particularly welcome the proven clinical
performance of Visia™ in the automatic detection, evaluation and follow-up
of pulmonary nodules and the ability to effortlessly integrate the system
in ex-isting IT environments to improve their clinical/medical workflows.'

Coinciding with the market launch of Visia™, the Philips Healthcare
subsidiary company Invivo Corp. has been gained as a new sales and
marketing partner. Invivo is one of MeVis Medical Solutions’ main industry
partners. Moreover, MeVis Medical Solutions and Invivo jointly developed
the DynaCAD® software solution for breast diagnosis and biopsies during MRT
scans, which is currently being supplemented with the addition of
innovative new applications.

Says Tynes: 'We are pleased to expand our partnership with Invivo and
leverage our collective sales & marketing resources to further expand the
distribution of this exciting and innovative new product. Due to the high
medical importance of this application, we are actively pursuing additional
global distribution possibilities and we plan to systemati-cally make use
of these. For this reason, we have decided for the first time to adopt a
new brand name for this product to highlight our position as an independent
producer of high-quality disease-oriented software solutions to clinical
end-users as well.'

The software solution originates from the computed tomography business
acquired from the Hologic subsidiary R2 Technology, Inc. in April. The
purchase also included rights to the R2 Technology expertise, intellectual
property, patents, source codes etc., and also existing industry
partnerships.

'Following on from the preliminary sales achieved in the third quarter from
the industry partnerships acquired from R2, we expect Visia™ business to
make a notable contribu-tion to consolidated sales in the upcoming
quarters,' says Dr. Olaf Sieker, CFO of MeVis Medical Solutions.
20.10.2008 Financial News transmitted by DGAP

---

Language: English
Issuer: MeVis Medical Solutions AG
Universitätsallee 29
28359 Bremen
Deutschland
Phone: +49 421 330 74-0
Fax: +49 421 330 74-50
E-mail: ir@mevis.de
Internet: http://www.mevis.de
ISIN: DE000A0LBFE4
WKN: A0LBFE
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, München, Düsseldorf, Stuttgart

End of News DGAP News-Service

---